TELO Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $40.24M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $0.89 - $2.09

2.7 Year TELO Performance Metrics:

Total Return (with DRIP): -83.3% (-48.45% CAGR)

Total Return (no DRIP): -83.3% (-48.45% CAGR)

Share Price: -83.3% (-48.45% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $1,671

Total Return $ (with DRIP): -$8,329

TELO Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

TELO Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for TELO

Based on past 2.7-year performance, here are TELO growth metrics:

Share price CAGR of -48.45%
Dividend CAGR of +0%

Using TELO CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	TELO (DRIP)	TELO - No DRIP
Current Price	$1.17	$1.17
Start Shares	8,547.01	8,547.01
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	8,547.01	8,547.01
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.01	$1.17
Total Dividends	$0	$0
Final Value	$50	$10,000

Estimated Future Value + Dividends - TELO

NOTE: Above numbers are our estimate based on TELO's Dividend and Price CAGR over past 2.7 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Telomir Pharmaceuticals, Inc. (TELO) had its IPO on , and is traded on NASDAQ stock exchange.

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. Its lead program centers on Telomir-1, an oral small molecule being studied for its ability to regulate metal ions and support cellular processes linked to telomere maintenance, epigenetic control, and inflammatory pathways. The company’s research spans a range of therapeutic areas, including oncology, metabolic disorders, ophthalmology, and neurodegenerative conditions. Telomir Pharmaceuticals, Inc. positions its platform around targeting underlying mechanisms rather than isolated symptoms, with current work aimed at advancing therapies for conditions such as triple-negative breast cancer, Wilson’s disease, type 2 diabetes, age-related macular degeneration, Alzheimer’s disease, and Progeria. The company is headquartered in Tampa, Florida.

TELO website: https://telomirpharma.com